07-374
Anti-phospho-KDR/Flk-1/VEGFR2 (Tyr1214) Antibody
Upstate®, from rabbit
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Größe auswählen
200 μG
CHF 331.00
Alle Fotos(1)
Größe auswählen
Ansicht ändern
200 μG
CHF 331.00
About This Item
UNSPSC-Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Biologische Quelle
rabbit
Qualitätsniveau
Antikörperform
purified antibody
Antikörper-Produkttyp
primary antibodies
Klon
polyclonal
Speziesreaktivität
mouse, human
Hersteller/Markenname
Upstate®
Methode(n)
western blot: suitable
Isotyp
IgG
NCBI-Hinterlegungsnummer
UniProt-Hinterlegungsnummer
Versandbedingung
dry ice
Posttranslationale Modifikation Target
phosphorylation (pTyr1214)
Angaben zum Gen
human ... KDR(3791)
Spezifität
phospho-KDR/VEGFR2 (Tyr1214)
Immunogen
(...FHpYDN...) in which pY corresponds to phosphorylated tyrosine at residue 1214 of human KDR/VEGFR2. Tyr1214 of human KDR corresponds to Tyr1212 in the mouse protein.
Anwendung
Research Category
Zelluläre Signaltransduktion
Zelluläre Signaltransduktion
Research Sub Category
Wachstumsfaktoren & -rezeptoren
Wachstumsfaktoren & -rezeptoren
Anti-phospho-KDR/Flk-1/VEGFR2 (Tyr1214) Antibody detects level of phospho-KDR/Flk-1/VEGFR2 (Tyr1214) & has been published & validated for use in WB.
Qualität
routinely evaluated by immunoblot RIPA lysates from porcine aortic endothelial cells expressing human CSF-1R/murineVEGFR-2 chimera
Zielbeschreibung
200-230 kDa
Physikalische Form
Protein A purified
0.1M Tris-glycine, pH 7.4, 0.15M NaCl,0.05% sodium azide before the addition of glycerol to 30%
Format: Purified
Lagerung und Haltbarkeit
2 years at -20°C
Rechtliche Hinweise
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Haftungsausschluss
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Sie haben nicht das passende Produkt gefunden?
Probieren Sie unser Produkt-Auswahlhilfe. aus.
Lagerklassenschlüssel
10 - Combustible liquids
WGK
WGK 1
Analysenzertifikate (COA)
Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Substitution of C-terminus of VEGFR-2 with VEGFR-1 promotes VEGFR-1 activation and endothelial cell proliferation.
Meyer, Rosana D, et al.
Oncogene, 23, 5523-5531 (2004)
Michael J Donovan et al.
European journal of cancer (Oxford, England : 1990), 45(8), 1518-1526 (2009-03-11)
To identify clinical and biometric features associated with overall survival of patients with advanced refractory non-small-cell lung cancer (NSCLC) treated with gefitinib. One hundred and nine diagnostic NSCLC samples were analysed for EGFR mutation status, EGFR immunohistochemistry, histologic morphometry and
V Dayanir et al.
The Journal of biological chemistry, 276(21), 17686-17692 (2001-03-30)
Activation of vascular endothelial growth factor receptor-2 (VEGFR-2) plays a critical role in vasculogenesis and angiogenesis. However, the mechanism by which VEGFR-2 activation elicits these cellular events is not fully understood. We recently constructed a chimeric receptor containing the extracellular
Rosana D Meyer et al.
The Journal of biological chemistry, 277(30), 27081-27087 (2002-05-25)
Vascular endothelial growth factor receptor (VEGFR)-2 plays a critical role in vasculogenesis during embryonic development and pathological angiogenesis, but little is known about the molecular mechanisms governing its functions. Here we investigated the role of tyrosine 1212 on mouse VEGFR-2
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.
Albert, DH; Tapang, P; Magoc, TJ; Pease, LJ; Reuter, DR; Wei, RQ; Li, J; Guo, J; Bousquet et al.
Molecular Cancer Therapeutics null
Active Filters
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.
